Literature DB >> 25196639

Exploring the active conformation of cyclohexane carboxylate positive allosteric modulators of the type 4 metabotropic glutamate receptor.

Xavier Rovira1, Youssef Harrak, Ana Trapero, Patricia González-Bulnes, Fanny Malhaire, Jean-Philippe Pin, Cyril Goudet, Jesús Giraldo, Amadeu Llebaria.   

Abstract

The active conformation of a family of metabotropic glutamate receptor subtype 4 (mGlu4 ) positive allosteric modulators (PAMs) with the cyclohexane 1,2-dicarboxylic scaffold present in cis-2-(3,5-dichlorophenylcarbamoyl)cyclohexanecarboxylic acid (VU0155041) was investigated by testing structurally similar six-membered ring compounds that have a locked conformation. The norbornane and cyclohexane molecules designed as mGlu4 conformational probes and the enantiomers of the trans diastereomer were computationally characterized and tested in mGlu4 pharmacological assays. The results support a VU0155041 active conformation, with the chair cyclohexane having the aromatic amide substituent in an axial position and the carboxylate in an equatorial position. Moreover, the receptor displays enantiomeric discrimination of the chiral PAMs. The constructed pharmacophore characterized a highly constrained mGlu4 allosteric binding site, thus providing a step forward in structure-based drug design for mGlu4 PAMs.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  GPCRs; allosteric modulators; conformational probes; metabotropic glutamate receptors; norbornanes

Mesh:

Substances:

Year:  2014        PMID: 25196639     DOI: 10.1002/cmdc.201402190

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  1 in total

1.  Challenges in the Discovery and Optimization of mGlu2/4 Heterodimer Positive Allosteric Modulators.

Authors:  Mark Gallant Fulton; Matthew Thomas Loch; Caroline Anne Cuoco; Alice Lambert Rodriguez; Emily Days; Paige Newton Vinson; Krystian Andrezej Kozek; Charles David Weaver; Anna Louise Blobaum; Peter Jeffrey Conn; Colleen Marie Niswender; Craig William Lindsley
Journal:  Lett Drug Des Discov       Date:  2019-12       Impact factor: 1.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.